Study S001773

A Study to Observe the Progress of Diabetes After Supaglutide Injection for 52 or 28 Weeks Treatment in Type 2 Diabetes Patients

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06605287
Study type: OBSERVATIONAL
Status: UNKNOWN
Enrollment: 100
Start: 2023-03-13
Primary completion: 2024-12-31
Lead sponsor: Nanjing First Hospital, Nanjing Medical University
Conditions: Type 2 Diabetes Mellitus
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

The clinical remission rate of diabetes [48 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0009523	Diabetes Remission in Drug-Naïve Patients with Type 2 Diabetes After Efsubaglutide Alfa Treatment. Sun R, Advances in therapy	2026	Randomized trial	PMID 41498879 DOI	cites ClinicalTrials.gov:NCT06605287; registry reference DERIVED:41498879